Loncastuximab Tesirine 和 Rituximab 联合 DA-EPOCH-R 用于治疗高危弥漫性大 B 细胞淋巴瘤患者
Loncastuximab Tesirine 和 Rituximab (Lonca-R) 继以 DA-EPOCH-R 治疗先前未治疗的高危弥漫性大 B 细胞淋巴瘤的 2 期研究
This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastuximab tesirine is a monoclonal antibody called loncastuximab, linked to a drug called tesirine. It is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs such as doxorubicin, vincristine, and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving loncastuximab tesirine and rituximab in combination with dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone may be more effective at treating high risk diffuse large B-cell lymphoma patients than standard treatments.
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVE:
I. To obtain a preliminary estimate of the anti-tumor activity of loncastuximab tesirine and rituximab (lonca-R) in newly diagnosed double-expressor lymphoma (DEL) and double-hit lymphoma (DHL).
SECONDARY OBJECTIVES:
I. To obtain additional efficacy measures of lonca-R in newly diagnosed DEL and DHL.
II. To assess safety and tolerability of lonca-R followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone (DA-EPOCH-R) as coded by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.
OUTLINE:
Patients receive rituximab intravenously (IV), loncastuximab tesirine IV, etoposide IV, doxorubicin IV, vincristine IV, prednisone orally (PO), and cyclophosphamide IV on study. Patients also undergo collection of blood samples and bone marrow aspiration and biopsy at screening and computed tomography (CT) or positron emission tomography (PET)/CT at screening, throughout the study, and during follow up.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
California
-
Sacramento、California、美国、95817
- University of California Davis Comprehensive Cancer Center
-
San Diego、California、美国、92037
- UC San Diego Moores Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Histologically or cytologically confirmed untreated DEL and DHL diffuse large B-cell lymphoma (DLBCL) meeting the World Health Organization (WHO) criteria for DEL - MYC greater than 40% and BCL2 greater than 50% by immunohistochemistry, or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit and/or triple-hit are included)
-
Measurable disease by CT or PET/CT scan, with one or more sites of disease >= 1.5 cm in longest dimension
-
Age >= 18 years at time of consent
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Life expectancy >= 6 months
-
Leukocytes >= 2,500/uL
-
Absolute neutrophil count >= 1,000/uL
-
Platelets >= 100,000/uL
-
Hemoglobin >= 8 g/dL
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN (AST and/or ALT =< 5 x ULN for patients with liver involvement)
-
Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
-
Creatinine clearance >= 30 mL/min by Cockcroft-Gault
-
Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)
-
Transthoracic echocardiography (TTE) or multigated acquisition scan (MUGA) ejection fraction greater than 40%
-
Women of child-bearing potential (WOCBP) must agree to use a highly effective method of contraception from the time of giving informed consent until at least 10 months after the last dose of study drug. Men with female partners who are of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 7 months after the last dose of study drug
-
Ability to understand and the willingness to sign a written informed consent document
-
Human immunodeficiency virus (HIV) infected patients:
- No history of acquired immunodeficiency syndrome (AIDS)-defining conditions other than lymphoma or history of CD4+ T-cells below 200/mm^3 prior to beginning combination anti-retroviral therapy (ART)
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- At time of study entry CD4+ T-cells must have recovered from prior lymphoma therapy to >= 250/mm^3
- At the time of study entry, the HIV viral load must be undetectable by standard laboratory assay
- During prior lymphoma therapy, patients must not have experienced documented infections attributed to the HIV positive (+) status
- No history of non-adherence to ART and willing to adhere to ART while on study
- Antiretroviral drugs with overlapping or similar toxicity profiles as study agents not allowed
Exclusion Criteria:
-
Current/ prior use of:
-
Lymphoma treatment, except for:
- 1 cycle of DA-EPOCH-R or rituximab, cyclophosphamide, doxorubicin (Adriamycin) vincristine (Oncovin) and prednisolone (R-CHOP)
- Radiotherapy > 2 weeks of initiating study treatment
- Nitrosoureas or mitomycin C > 6 weeks of initiating study treatment
- Steroid treatment for DLBCL or steroid monotherapy to stabilize disease while awaiting fluorescence in situ hybridization (FISH)
- Other cancer therapies (e.g., prostate, breast hormonal-based therapy) per the principal investigator's discretion
-
Anthracycline greater than 50 mg/m^2 (total lifetime) for a prior malignancy
-
Complementary and alternative medications (CAM) within 1 week prior to initiating study treatment
-
Treatment with any other investigational agent for any indication within 3 weeks prior to initiating study treatment
-
Loncastuximab tesirine or rituximab with progression within 6 months of initiating study treatment
-
Oral or intravenous (IV) antibiotics within 2 weeks prior to initiating study treatment. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
-
Live, attenuated influenza vaccine within 4 weeks prior to initiating study treatment
-
-
Immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor, such as anti-tumor necrosis factor [TNF] agents) within 14 days prior to initiating study treatment. The following are exceptions to this criterion:
- Steroids
- Bisphosphonate therapy for symptomatic hypercalcemia or for other reasons (e.g., bone metastasis or osteoporosis)
-
Known uncontrolled central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement
-
History of hypersensitivity to anti-CD19 antibodies, loncastuximab tesirine, or any agents used in DA-EPOCH-R
-
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
-
Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
-
Breastfeeding or pregnancy
-
Clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; or inherited liver disease
- Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HbsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
-
Documented eczema, psoriasis, or lichen simplex chronicus of vitiligo with dermatologic manifestations (e.g., patients with psoriatic arthritis would be excluded), unless the following apply:
- Affected skin covers less than 10% of body surface area (BSA)
- Disease is well controlled at baseline and only requires low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
- No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
-
Known active tuberculosis (TB)
-
Severe infections within 4 weeks prior to initiating study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
-
Major surgical procedure within 28 days prior to initiating study treatment or anticipation of need for a major surgical procedure during the course of the study
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment (Lonca-R, DA-EPOCH-R)
Patients receive rituximab IV, loncastuximab tesirine IV, etoposide IV, doxorubicin IV, vincristine IV, prednisone PO, and cyclophosphamide IV on study. Patients also undergo collection of blood samples and bone marrow aspiration and biopsy at screening and CT or PET/CT at screening, throughout the study, and during follow up. |
Given IV
其他名称:
Given PO
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Complete response rate
大体时间:First dose through cycle 2 (1 cycle = 3 weeks)
|
Evaluated per 2014 Lugano criteria. An exact 95% confidence interval will be calculated. |
First dose through cycle 2 (1 cycle = 3 weeks)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall survival rate
大体时间:First dose to off study, assessed up to 3 years
|
Will be estimated using the product-limit of Kaplan and Meier. |
First dose to off study, assessed up to 3 years
|
|
Relapse/progression free survival
大体时间:First dose (cycle 1 day 6 rituximab dose) until relapse/progression or off study, whichever occurs first, assessed up to 3 years
|
Will be estimated using the product-limit of Kaplan and Meier. |
First dose (cycle 1 day 6 rituximab dose) until relapse/progression or off study, whichever occurs first, assessed up to 3 years
|
|
Overall response rate (complete response + partial response)
大体时间:First dose through cycle 2 (1 cycle = 3 weeks)
|
Defined as the proportion of participants who have partial or complete response from the start of study treatment through completion of 2 cycles. Evaluated per 2014 Lugano criteria. An exact 95% confidence interval will be calculated. |
First dose through cycle 2 (1 cycle = 3 weeks)
|
|
Incidence of adverse events
大体时间:First dose through 30 days post last dose
|
Will evaluate the number of participants experiencing treatment-related adverse events, classified by severity and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Observed toxicities will be summarized by type (organ affected or laboratory determination), severity, date of onset, duration, and attribution. |
First dose through 30 days post last dose
|
合作者和调查者
调查人员
- 首席研究员:Joseph M Tuscano、University of California, Davis
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 氨基酸,肽和蛋白质
- 蛋白质
- 有机化学品
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 碳氢化合物
- 碳氢化合物,循环
- 碳水化合物
- 生物碱
- Podophyllotoxin
- 四氢乙烯甲烯烃
- 萘
- 多环芳烃
- 碳氢化合物,芳香族
- 多环化合物
- 葡萄糖剂
- 糖苷
- 吲哚
- 抗体,单克隆
- 抗体
- 免疫球蛋白
- 免疫蛋白
- 血蛋白
- 血清球蛋白
- 球蛋白
- 怀孕
- 怀孕
- 类固醇
- 融合环化合物
- 磷酰胺芥末
- 氮芥末化合物
- 芥末化合物
- 碳氢化合物,卤素
- 磷酰胺
- 有机磷化合物
- 妊娠二培养子
- VINCA生物碱
- Secologanin色素生物碱
- 吲哚生物碱
- 吲哚衍生物
- 吲哚王
- 蒽环类动物
- 萘烯
- 氨基糖苷
- 抗体,单克隆,鼠的衍生
- Daunorubicin
- 利妥昔单抗
- 强的松
- 环磷酰胺
- 依托泊苷
- 阿霉素
- 长春新碱
- CT-P10
- Deltacortene
- prepnylidene
- Loncastuximab Tesirine
其他研究编号
- UCDCC#303
- P30CA093373 (美国 NIH 拨款/合同)
- UCDCC#303 (其他标识符:University of California Davis Comprehensive Cancer Center)
- NCI-2022-07762 (注册表标识符:CTRP (Clinical Trial Reporting Program))
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.